


PRODUCT INFORMATION



NXY-059

Item No. 22109

CAS Registry No.: 168021-79-2
Formal Name: 4-[[[(1,1-dimethylethyl)oxidoimino]methyl]-1,3-benzenedisulfonic acid, disodium salt
Synonyms: CPI-22, Disufenton Sodium
MF: C₁₁H₁₃NO₇S₂ • 2Na
FW: 381.3
Purity: ≥98%
UV/Vis.: λ_{max}: 203, 235, 305 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

NXY-059 is supplied as a crystalline solid. A stock solution may be made by dissolving the NXY-059 in the solvent of choice, which should be purged with an inert gas. NXY-059 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of NXY-059 in ethanol is approximately 2 mg/ml and approximately 20 mg/ml in DMSO and DMF.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of NXY-059 can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of NXY-059 in PBS, pH 7.2, is approximately 10 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

NXY-059 is a nitron free radical spin trap with neuroprotective properties.¹⁻³ It inhibits transport of tissue plasminogen activator (tPA) from the luminal to the abluminal compartment in an *in vitro* model of the blood-brain barrier (BBB) under ischemic conditions at a concentration of 250 μM.⁴ NXY-059 (10 mg/kg per h) decreases infarct volume by 59% in a rat model of transient ischemia induced by occlusion of the middle cerebral artery (MCA).² It decreases functional disability in the hemiparetic arm of marmosets in the Hill-and-Valley staircase, two-tube choice, and six-tube search tests following MCA occlusion-induced ischemia when administered at a dose of 16 mg/kg per hour.³

References

1. Maples, K.R., Ma, F., and Zhang, Y.-K. *Free Radic Res.* **34**(4), 417-426 (2001).
2. Sydserff, S.G., Borelli, A.R., Green, A.R., *et al.* *Br. J. Pharmacol.* **135**(1), 103-112 (2002).
3. Marshall, J.W.B., Duffin, K.J., Green, R., *et al.* *Stroke* **32**(1), 190-198 (2001).
4. Culot, M., Mysiorek, C., Renftel, M., *et al.* *Brain Res.* **1294**, 144-152 (2009).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/22/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM